This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.

Inclusion Criteria:

• Age 18 years or older
• Scheduled for clinical brain MRI with gadolinium contrast
• Known or suspected brain metastases
• Able to provide informed consent
• Able to lie still for the duration of the MRI examination

Exclusion Criteria:

• Contraindications to MRI
• Known allergy or contraindication to gadolinium-based contrast agents
• Renal impairment (eGFR < 30 mL/min/1.73m²)
• Pregnant or breastfeeding
• Inability to comply with study procedures

Patients referred for clinical brain MRI with contrast at a university hospital radiology department in Sweden. Participants will be adults with known or suspected brain metastases undergoing routine post-gadolinium imaging as part of their diagnostic work-up.